We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
George Yaghmour
Jul 15, 2015
The NCCN Kidney cancer panel considers Everolimus and Axitinib categories 1 for Subsequent therapy for patients with mRCC clear cell predominance especially after TKI therapy. According to the RECORD 1 trial (Everoimus), and phase III (AXIS) Study (Axitinib).
Both Everolimus and Axitinib undergoes extensive hepatic metabolism, as they are a CYP3A4 substrate. Oxcarbazapine is a CYP3A4 inducer and will decrease the level or effect of Everolimus, and Axitinib oral, primarily through the CYP3A4 isoenzyme.
Efficacy and safety of temsirolimus were demonstrated at a second interim analysis of the ARCC trial, a phase III study in previously untreated patients with advanced RCC and considered as a category 1 recommendation for first-line treatment of poor-risk patients predominantly clear cell stage IV renal carcinoma.
The NCCN Panel considers temsirolimus as category 2B recommendation after a TKI according to phase III trial (INTORSECT) comparing the efficacy of temsirolimus to sorafenib following first-line sunitinib as a treatment for patients with RCC, on top of that Temsirulimus is also a CYP3A4 substrate.
Other TKI like Sorafinib and Sunitinib also undergoes extensive hepatic metabolism, as they are a CYP3A4 substrates and are both are category 2 A recommendation. Bevacizumab is a category 2B recommendation after a TKI according to phase II trial.
Everolimus treatment associated with common adverse effects, more than 30-50% of anemia, hyperglycemia, hypercholesterolemia, mucositis, fatigue, and rash.
In this case obviously the patient is not getting the adequate dose, and switching the Anti-seizure medication is the important point to consider in this situation. Would still consider after stopping the Oxcarbazapine to either continue the Everolimus, or Axitinib which would be reasonable choice. Would also consider clinical trial or PD1/PDL1 according to molecular and genetics testings. Avastin, Temserolimus and other TKIs are resonable options if progressed further.
Mar 28, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
George Yaghmour
Jul 15, 2015
Mar 28, 2024
Pending Moderator approval.